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Cohort profile
AbstrACt 
Purpose The prevalence of chronic non-communicable 
diseases (NCDs) is increasing worldwide. NCDs are the 
leading cause of both morbidity and mortality, and it 
is estimated that by 2030, they will be responsible for 
80% of deaths across the world. The Genomes for Life 
(GCAT) project is a long-term prospective cohort study 
that was designed to integrate and assess the role of 
epidemiological, genomic and epigenomic factors in the 
development of major chronic diseases in Catalonia, a 
north-east region of Spain.
Participants At the end of 2017, the GCAT Study 
will have recruited 20 000 participants aged 40–65 
years. Participants who agreed to take part in the 
study completed a self-administered computer-driven 
questionnaire, and underwent blood pressure, cardiac 
frequency and anthropometry measurements. For each 
participant, blood plasma, blood serum and white blood 
cells are collected at baseline. The GCAT Study has access 
to the electronic health records of the Catalan Public 
Healthcare System. Participants will be followed biannually 
at least 20 years after recruitment. 
Findings to date Among all GCAT participants, 59.2% 
are women and 83.3% of the cohort identified themselves 
as Caucasian/white. More than half of the participants 
have higher education levels, 72.2% are current workers 
and 42.1% are classified as overweight (body mass 
index ≥25 and <30 kg/m2). We have genotyped 5459 
participants, of which 5000 have metabolome data. 
Further, the whole genome of 808 participants will be 
sequenced by the end of 2017.
Future plans The first follow-up study started in 
December 2017 and will end by March 2018. Residences 
of all subjects will be geocoded during the following year. 
Several genomic analyses are ongoing, and metabolomic 
and genomic integrations will be performed to identify 
underlying genetic variants, as well as environmental 
factors that influence metabolites.
IntroduCtIon   
The prevalence of chronic non-communi-
cable diseases (NCDs) is increasing world-
wide.1–3 NCDs, such as cardiovascular 
diseases, cancer, respiratory diseases and 
diabetes, are characterised as having a long 
duration and a slow progression. NCDs are 
currently the leading cause of both morbidity 
and mortality, and it is estimated that by 
2030, they will be responsible for 80% of 
deaths across the world.4 Cancer affected 
around 3.45 million Europeans in 2012 and 
caused 1.75 million deaths.5 In 2015, almost 
248 000 new cancer cases were diagnosed in 
Spain, with colorectal, prostate, lung, breast 
and urinary bladder cancers being the five 
most common.6 The morbidity and mortality 
rates of these conditions, together with 
other chronic disorders (ie, obesity, asthma, 
arthritis) are responsible for the high burden 
on public healthcare system expenses. There-
fore, there exists a huge interest in devel-
oping and implementing new predictive and 
prognostic methods, as well as in adopting 
new public health strategies to reduce their 
socioeconomic impact.7
strengths and limitations of this study
 ► The only currently available population-based pro-
spective cohort study in Spain with more than 5500 
genotyped participants and 800 whole genome 
sequences.
 ► Long period of follow-up: 20 years; participants will 
be contacted again biannually.
 ► Blood plasma, blood serum and white blood cells 
are collected and stored at baseline for each partic-
ipant; detailed epidemiological and anthropometric 
measurements;  access to electronic health re-
cords (EHR)of the Catalan Public Healthcare System 
that will allow researchers to have both retrospec-
tive and prospective data.
 ► The Genomes for Life  (GCAT) Study will integrate 
and assess the role of epidemiological, environ-
mental, EHR and omic factors in the development of 
chronic diseases (ie, by using molecular pathologi-
cal epidemiology analyses).
 ► The GCAT cohort is mainly based on volunteer mem-
bers of the Blood and Tissue Bank of Catalonia.
2 Obón-Santacana M, et al. BMJ Open 2018;8:e018324. doi:10.1136/bmjopen-2017-018324
Open Access 
Individual susceptibilities to develop NCDs as well as 
their progression are influenced by genetic, epigenetic 
and environmental factors, and their interaction (also 
known as gene-environment interaction).8–10 During 
the last decade, many studies have assessed the associa-
tion between genetic variability and disease, both with 
candidate gene approaches and with comprehensive and 
agnostic genome-wide analysis (genome-wide association 
studies; GWAS). These studies have focused on common 
variant analysis of single nucleotide polymorphisms 
(SNPs) and have identified more than 36 000 risk loci for 
more than 60 common diseases.11 However, the relative 
risks (RRs) reported are too low to be clinically relevant, 
and do not take into consideration the contribution of 
rare and structural variants.12 13 There is strong evidence 
that rare genetic variation is important for disease predis-
position.14 15 Next-generation sequencing technologies 
allow the identification of novel rare variants, and may aid 
in increasing our understanding of the biology of cancer 
susceptibility and complex traits.16 The role of epigenetic 
variation in disease susceptibility is an important factor to 
consider, either influenced by underlying genetic variants 
or modulated by the impact of the environment.
There is also robust epidemiological evidence from 
ecological studies that changes in the environmental 
exposures affect cancer and other diseases' incidence and 
mortality, suggesting that genetic predisposition cannot 
explain the whole incidence/mortality variability between 
countries.17–19 In fact, WHO listed tobacco, high blood 
pressure, overweight and obesity, physical inactivity, high 
blood glucose, high cholesterol, low fruit and vegetable 
intake, urban outdoor air pollution, alcohol consump-
tion, and occupational risks as the major risk factors in 
high-income countries.20 Thus, it is important to design 
and develop new primary and secondary prevention strat-
egies to reduce these exposures or mitigate their impact 
on NCD incidence and mortality.
Cohort studies have long been used to study deter-
minants of disease and are considered to produce the 
highest level of evidence among observational studies. 
Longitudinal studies, such as prospective cohort studies, 
have a straightforward design. Information is collected at 
the time of recruitment, when the study population is free 
of disease, preferentially with repeated measurements. 
The population is followed over time, until the emer-
gence of the outcomes of concern (ie, cancer, cardio-
vascular disease, diabetes, asthma). This design allows 
researchers to evaluate comparisons between exposed 
and unexposed subjects, and assess the magnitude of the 
associations using relative and absolute measures of risk 
or effect, and are less to prone to information biases than 
retrospective designs.21
The Genomes for Life (GCAT) Study is a long-term 
project that was set up to integrate and assess the role 
of epidemiological, environmental and omic factors (ie, 
genomic, metabolomic, proteomic, epigenomic) in the 
development of chronic diseases. Furthermore, GCAT 
also aims to assess the prevalence of risk factors and their 
association with disease incidence over time. Different 
but complementary lines of research will be pursued 
between genetic susceptibility and potential risk factors 
(the large sample size for some NCDs will allow the study 
of gene-gene and gene-environment interactions), the 
relation between several biomarkers in blood (ie, dietary, 
inflammatory, metabolomic, hormonal) and diseases, 
and the associations between epidemiological risk factors 
and diseases. These objectives will provide an excep-
tional opportunity to explore the association between 
the genome and the phenome of a large number of 
participants, since the GCAT Study will address different 
outcomes. The present article provides a comprehensive 
description of the GCAT Study.
Cohort desCrIPtIon
study design, population, recruitment
The GCAT project is a prospective cohort study that was 
designed to recruit the general population of the north-
east region of Spain, Catalonia, with a population of 
7522 596 inhabitants. From April 2014 to June 2014, a 
pilot study (including 191 participants) was conducted in 
two centres to assess the feasibility of the study, and there-
after the project started.
The cohort is open to any volunteer that requests to 
participate; however, to improve recruitment, the GCAT 
cohort are individuals mostly enrolled from blood donors 
invited through the Blood and Tissue Bank (BST), a 
public agency of the Catalan Department of Health that 
guarantees the supply and proper use of human blood 
and tissue in Catalonia (http://www. bancsang. net/ en_ 
index/). With the aim to identify chronic disease events 
in the mid-term, the study covers a middle-aged range 
(40–65 years old) corresponding to 30% of the Catalan 
population.22 In addition, participants are required to 
be able to understand at least one of the two official 
languages in Catalonia (Catalan or Spanish) to provide 
written informed consent, to possess an Individual Health 
System Identification Card and to be current residents 
of Catalonia. Potential participants are excluded if they 
have mental or health impairment disorders that impede 
giving written informed consent or efficient communica-
tion, or if they are planning to leave Catalonia during the 
following 5 years.
Participants are invited to participate using multiple 
active strategies, such as phone call, mail, GCAT web 
page (http://www. genomesforlife. com/ participants/) or 
in person. Then, an appointment is agreed on and partic-
ipants are asked to attend a recruitment centre. There are 
11 permanent recruitment centres (figure 1).
Although there is no attempt to obtain a truly repre-
sentative sample of the general population, in addition 
to the permanent centres, a large number of temporal 
recruitment centres are been organised all over Catalonia 
to accelerate recruitment. Recruitment is also open to 
any volunteer who meets the above criteria and is willing 
to participate. In this case, volunteers should ask for an 
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appointment by phone or via our GCAT web page after 
filling in a registration form. All participants who agree 
to be part of the study provided an informed consent and 
are asked to sign a consent agreement form that allows 
permission to access electronic health records (EHRs) for 
passive follow-up and to be contacted regularly to collect 
follow-up information collection on lifestyle and disease 
events. Participants are free to leave the study or withdraw 
their consent for specific areas of research. 
Participants who agree to take part in the study complete 
an epidemiological questionnaire, donate a blood sample 
and undergo blood pressure, cardiac frequency and 
anthropometry measurements. All biological and physical 
examinations are performed in a separate room. Baseline 
interviews are performed by trained healthcare profes-
sionals (doctors and nurses). Specific guidelines were 
designed by the GCAT scientific members to support the 
interviewers, and to ensure uniform data collection.
epidemiological questionnaire
Epidemiological interviews are done in a designated 
area using dedicated computers to ensure privacy. The 
electronic computer-based epidemiological question-
naire is included in the eGCAT software, which allows a 
comprehensive tracking of all the recruitment process.23 
The eGCAT is an adapted version of Onyx (www. obiba. 
org).24 Customisation in local languages was performed 
in collaboration with the software developers at the Mael-
strom Research Group, Research Institute of the McGill 
University Health Centre Montreal, Canada. A paper 
questionnaire was also designed in case of system failure 
or computer illiteracy.
Figure 1 Genomes for Life (GCAT) recruitment centres. Distribution of the 11 GCAT permanent recruitment centres across the 
Catalan territory.
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Participants complete a self-administered comput-
er-based questionnaire that collects data on a large 
number of lifestyle and health factors that are of interest 
in epidemiological and genetic studies. The GCAT base-
line epidemiological questionnaire was specially designed 
to facilitate interoperability and collaboration with other 
survey studies. All variables measured in the GCAT Study 
are grouped in ‘Group Theme and Domain’, as proposed 
by the international guidelines for harmonisation of 
prospective population-based cohorts.24 25
The baseline survey includes 142 and 149 questions for 
men and women, respectively. Detailed information is 
also assessed on sociodemographic and socioeconomic 
status, current and past occupation, physical activity, life-
time tobacco and alcohol consumption, diet, personal 
and familiar medical history (parents, sisters/brothers 
and sons/daughters), prescription drug use, as well as 
specific questions related to women’s or men’s health. 
All epidemiological variables can be examined at the 
MICA repository, a web application used to create web 
data portals for epidemiological or consortium studies 
(http:// gattaca. imppc. org/ gcat- mica/ mica/ study/ 
gcat).
Sociodemographic, socioeconomic and occupational variables 
assessment
Participants are required to fill in information on their 
gender, date and country of birth, current residence, 
ethnicity, laterality, marital status, social network, house-
hold incomes and type of healthcare access. Education 
levels are categorised as low (primary school, none), 
middle (vocational, secondary school, high school) and 
high (vocational postsecondary school, university studies 
or equivalent).
At enrolment, participants are asked about their 
current occupational status and type of job. The occu-
pations asked are categorised based on the Spanish 
National Occupation Classification (CNO-11),26 which 
derives from the International Standard Classification of 
Occupations (ISCO-08).27 For each job reported, detailed 
questions to ascertain time schedules (rotating, morning 
work, evening work, split duty, night work), total hours 
worked per week and occupational physical activity are 
assessed.
Tobacco and alcohol assessment
Detailed questions on lifetime history of tobacco smoking 
(including cigarettes, cigars, pipe, hand-rolling tobacco, 
electronic cigarettes and waterpipe tobacco) address 
information on current status, smoking intensity, total 
lifetime dosage of tobacco smoke (measured in pack-
years), age at initiation and cessation, and current/former 
number of cigarettes smoked per day. Further, second-
hand smoke exposure at home and at work are assessed 
both during childhood and adulthood. An adapted and 
reduced version of the Fagerström Test, also known as the 
Heaviness of Smoking Index, is used to estimate nicotine 
dependence.28
Participants report the average number of standard 
glasses of wine, beer, champagne, sweet liquor or distilled 
spirits drunk per day or per week over the year before 
recruitment. Average volume of alcohol consumption per 
day is assessed using the ‘standard drink unit’, which is 
equivalent to 10 g of ethanol, and has been validated and 
extensively used in Spanish cohorts.29 Participants are 
categorised based on drinking status, drinking patterns 
or alcohol intake following the WHO-alcohol classifica-
tion.30 Gender differences in drinking habits are also 
taken into account:31men are classified into six categories 
(former, never, low, moderate, high and very high intake) 
whereas five categories are defined for women (former, 
never, low, moderate and high intake).
Physical activity assessment
A validated short version of the European Prospective 
Investigation into Cancer and Nutrition (EPIC) Physical 
Activity Questionnaire (PAQ) is used to assess free-living 
activity referring to the past 12 months.32 The GCAT Ques-
tionnaire slightly differed from the PAQ version, since 
the most frequent sports in Catalonia/Spain were asked. 
All physical activities are coded using the Compendium 
of Physical Activities, and metabolic equivalent hours 
per week value are used to denote intensity.33 Following 
the recommendations, the ‘total physical activity index’ 
is assessed in three domains (leisure, occupational and 
housework PA), so that participants can be categorised 
into four levels (inactive, moderately inactive, moderately 
active and active).34
Dietary assessment
To estimate baseline adherence to the Mediterranean 
diet among GCAT participants we used the 14-item Medi-
terranean Diet Adherence Screener, a validated question-
naire that can be used in large epidemiological studies.35 
Additionally, a brief semiquantitative Food Frequency 
Questionnaire (FFQ), containing the food groups most 
eaten in Spain is used to assess total energy and macronu-
trient intake. A Spanish validated full-length FFQ (>128 
questions), with a time frame referring to the previous 12 
months, will be used during the first follow-up to assess 
dietary intake.36
Medical history, drug use and gender-specific information 
assessment
The medical history survey includes, among others, ques-
tions on current self-perceived health status (very good, 
good, fair, bad and very bad), minimum and maximal 
weight during the last 5 years and weight at birth. 
Current mental health is being assessed using the brief 
version of the Mental Health Inventory,37 and asthma is 
being evaluated by using a categorical and continuous 
asthma score.38 Specific questions for anti-inflammatory 
drugs and vitamin/mineral supplements use are also 
requested. Moreover, participants are asked whether a 
doctor has ever diagnosed 27 different diseases (table 1). 
If the answer is positive, then participants are asked for 
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the age at diagnosis and current drug use (drug name, 
frequency of use and age at first use). Drugs are being 
classified according to the Anatomical Therapeutic 
Chemical (ATC) Classification System.39 The query also 
contains exhaustive questions on family history of diseases 
(parents, brother(s)/sister(s), and son(s)/daughter(s)).
The specific women’s health questions are specially 
designed to assess a wide range of information on 
menstrual and reproductive history (including exogenous 
hormone use), and to study probable health variations 
in middle-aged women. Men are asked if they have ever 
been diagnosed with the most common prostate diseases 
(prostatitis or benign prostatic hyperplasia) and if they 
have ever taken any drug to treat them. Additionally, 
gender-specific screening programme participation is 
asked for both men and women.
Baseline environmental exposure assessment
Residences of all subjects will be geocoded, and a 
geographical information system based approach will be 
applied to evaluate environmental exposures (proximity 
to natural/green spaces, urban structure, air pollution, 
noise, temperature and artificial light at night) using 
existing information such as Urban Atlas, Corine Land 
Cover, Strategic Noise Maps (European Parliament direc-
tive 2002/49/CE and the Spanish Law 37/2003), Landsat 
images, International Space Station (ISS) images, among 
other available data.
Anthropometric measurements
Weight, height, waist and hip circumference (WC, HC; 
respectively), systolic and diastolic blood pressures, and 
heart rate are measured on all participants by trained 
personnel using the same protocol in all BST recruit-
ment centres. Height is measured with a stable stadiom-
eter (stable stadiometer for mobile height measurement, 
Seca 217, SECA UK), and weight is measured with elec-
tronic flat scales (bearing capacity of up to 200 kg, Seca 
813, SECA, UK). Body circumference is measured using 
a measuring tape (ergonomic circumference measuring 
tape, Seca 201, SECA, UK) based on the WHO STEP-
wise Approach to Surveillance (STEPS) protocol.40 WC 
is taken at the midpoint between the lower margin of the 
last palpable rib and the top of the iliac crest (expressed in 
cm). HC is taken at the maximum circumference over the 
buttocks (expressed in cm). All anthropometric measure-
ments are performed in light clothing and twice. In case 
of discordances a third measure is taken. The average 
of the measures will be used for data analysis. A digital 
automatic blood pressure monitor (HEM-705CP, Omron 
Corporation, Tokyo, Japan) is used to measure systolic 
and diastolic blood pressures and heart ratio, which are 
displayed simultaneously. Participants are asked to sit and 
rest at least 5 min before taking three measurements (left 
arm). Interviewers wait 2–3 min between measurements. 
The average of the second and third measures will be 
used for data analysis as suggested by the WHO STEP 
protocol.40 Body mass index (BMI; kg/m2), WC and waist-
to-hip ratio (WHR) will be categorised based on WHO 
guidelines.41
biobanking of samples
For each participant, blood plasma, blood serum and 
white blood cells are collected at baseline according to 
standardised procedures (table 2). Different preserva-
tives are used to collect blood specimens according to 
the downstream application.42 43 The leucocyte residue 
(LR) is the main source for DNA extraction. The LR is 
a highly concentrated buffy coat obtained after the ordi-
nary blood donation (blood bag of 480 mL). In those 
cases where blood donation is not possible or acceptable, 
an EDTA tube (10 mL) is obtained and used for DNA 









995.3 Allergies 3132 (16.97)
401.9 Hypertension 2771 (12.31)
346.90 Migraine disorders 1614 (8.75)
472.0 Rhinitis 1415 (7.67)
311 Depression disorder 1193 (6.46)
493.90 Asthma 985 (5.34)
692.9 Eczema 872 (4.73)
41.86 Helicobacter pylori infection 855 (4.63)
569.0 Colon and/or rectal polyps 727 (3.94)
696.8 Psoriasis 688 (3.73)
250.00 Diabetes mellitus 613 (3.32)
733.00 Osteoporosis 578 (3.14)
714.9 Arthritis 552 (2.99)
199.1 Cancer 405 (2.19)
Z14 Inborn genetic diseases 172 (0.93)
496
Chronic obstructive pulmonary 
disease 89 (0.48)
558 Chronic colitis 53 (0.29)
434 Stroke 51 (0.28)
573.3 Chronic hepatitis 38 (0.21)
410.90
Myocardial infarction, heart 
attack 36 (0.19)
413
Coronary heart disease/angina 
pectoris 35 (0.19)
710 Lupus erythematosus 30 (0.16)
560.89 Crohn's disease 19 (0.10)
295.90 Schizophrenia 17 (0.09)
331 Alzheimer's disease/dementia 2 (0.01)
332 Parkinson's disease 1 (0.01)
*The International Statistical Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM).
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extraction. Three vacutainer tubes with plasma separa-
tion tube (PST), serum separation tube (SST) and anti-
coagulant citrate dextrose (ACD) blood preservative are 
additionally collected for plasma, serum and viable cells, 
respectively.
The quality and quantity of the biospecimen samples is 
an important concern due to the GCAT long-term objec-
tives. The suitability for maximising downstream appli-
cations is assured by developing an efficient recruitment 
infrastructure, by setting up a quality control tracking 
plan and by following dedicated procedures.
The GCAT Study has a centralised model, with two 
central laboratories (BST and PMPPC) and the recruit-
ment satellites centres. Every day, samples are transported 
from all recruitment centres to the BST headquarters. 
From the ACD tubes, two aliquots of 1 mL are cryopre-
served with dimethyl sulfoxide in cryogenic vials. These 
vials are stored in two independent liquid nitrogen tanks 
(−196°C) at the BST local repositories. The blood bag is 
also processed at the BST headquarters laboratory, where 
the LR is aliquoted into 15 mL Falcon tubes. EDTA, PSTs 
and SSTs are shipped to the PMPPC laboratory 24 hours 
after blood extraction at 4°C, while LR Falcon tubes are 
shipped <48 hours after blood extraction at 4°C.
Once samples arrive at PMPPC they are processed 
for storage. EDTA tubes are centrifuged at 2500 g for 
10 min at 4°C, and the buffy coat is manually separated 
and aliquoted in tubes with 2D Data-Matrix codification 
(2D tubes) that fit in a 96-well plate Society for Biomo-
lecular Screening (SBS) standard format. The buffy 
coat is manually aliquoted in two 2D tubes of 0.5 mL. 
SSTs and PSTs are immediately centrifuged after blood 
extraction at recruitment centres (2000 g for 10 min 
at room temperature, after 30 min of clotting time). 
Further, plasma derived from PSTs is centrifuged for 
a second time at PMPPC (2000 g for 10 min at 4°C). 
From PSTs and SSTs, four aliquots of 0.45 mL in four 
2D tubes are made. From LR-Falcon tubes, two aliquots 
of 0.5 mL in two 2D tubes are derived. All samples 
aliquoted at PMPPC are processed using an automated 
liquid handling system (TECAN robot), and aliquots are 
stored in two independent ultra-freezers at −80°C with a 
CO2 backup system.
This recruitment plan standardises the collection 
methods to minimise sample variability. The preanalytical 
variability derived from extraction methods to storage is 
registered using a standard preanalytical code (SPREC). 
The SPREC code offers an unbiased resource to eval-
uate any unexpected downstream finding. Further, all 
samples are registered daily in a laboratory integrated 
management system (Abbott Informatics-STARLIMS) 
that allows complete sample processing traceability. The 
central GCAT laboratory located at PMPPC currently 
contains around 270 000 2D tubes from blood aliquots 
from 18 659 participants.
The BST headquarters laboratory routinely performs 
a viral/bacterial antigen exposure determination, 
including hepatitis B virus, hepatitis C virus, HIV I/II, 
human T-lymphotropic virus I/II, syphilis (Lues) and 
Chagas. These results are personally communicated to all 
GCAT participants by letter under internal protocols. In 
case of a positive result, the participant is encouraged to 
visit a medical doctor.
omic studies
In an early pilot study, omics techniques (ie, genome, 
metabolome, epigenome) will be used to determine 
molecular profiles from 6550 participants (6400 unre-
lated and 50 family trios) table 3. These 6400 unrelated 
participants were randomly selected from the GCAT 
cohort with a 1:1 gender proportion.
General metabolomic characterisation and specific 
lipoprotein profile of all 5000 blood plasma samples 
are currently being analysed using a combined untar-
geted approach of nuclear magnetic resonance spec-
troscopy and mass spectrometry at the Centre for Omic 
Table 2 Suitability and processing of collected samples










n (ToC) Control assay*
Genomic/epigenomic Buffy coat EDTA 10 4 max 
24 hours




Blood bag 480 18 max 
48 hours
2 (−80) SNP array, qPCR, PCR, 
STR
Proteomic/epigenomic Plasma PST 4.5 4 max 
24 hours
4 (−80) –
Serum SST 5 4 max 
24 hours
4 (−80) Circulating microRNAs 
integrity analysis
Functional/cell line DMSO blood ACD 6 18 – 2 (N2) EBV cell transformation 
and immortalisation
*Suitability downstream analysis performed in collected samples.
ACD, anticoagulant citrate dextrose; DMSO, dimethyl sulfoxide; EBV, Epstein-Barr virus; PMPPC, Program of Predictive and Personalized 
Medicine of Cancer; PST, plasma separation tube; qPCR, quantitative PCR; SNP, single nucleotide polymorphism; SST, serum separation 
tubes; STR, short tandem repeat.
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Sciences-Centre Tecnologic de Catalunya (COS-EU-
RECAT) in Reus, Tarragona, Spain (online supplemen-
tary table1).
From the 6400 unrelated participants, 5459  genomic 
profiles have been characterised by comprehensive geno-
typing. Genome-wide genotypes have been generated 
using Illumina Infinium SNP-bead array technology. We 
chose the Multi-Ethnic Global (MEGAEX, V.2) consor-
tium array, a multipurpose, multiethnic  genotyping 
array with two million selected markers (including previ-
ously described germline mutations, insertions-deletions 
(InDels) and SNPs).44 We have strictly followed the stan-
dard manufacturer recommended automated protocol 
for the Infinium HTS Assay scanned with a HiScan 
confocal scanner (Illumina, San Diego, California, USA). 
Genome Studio V.2011.1 has been used for raw data anal-
ysis. Genotyping was performed at the Genomics and 
Bioinformatics Unit of the PMPPC Institute for Health 
Science Research Germans Trias i Pujol, in Badalona, 
Spain.
A pilot family study including 50 related participants 
(parents and at least one offspring) is being conducted to 
reveal the role of DNA methylation as a key mechanism 
of heritability of chronic diseases. DNA methylation epig-
enomic profile of whole blood samples will be determined 
by Infinum Methylation EPIC 850K bead array assay.
Additionally, the entire genome of 808 participants 
will be sequenced with an overall coverage of 30×, using 
paired end sequencing by synthesis (SBS) on a HiSeq 
4000 sequencer from Illumina (Illumina, San Diego, 
California, USA). Methylation analysis will be performed 
at the Genomic and Bioinformatics platform at PMPPC, 
and whole genome sequencing at the National Center for 
Genomic Analysis (CNAG-CRG) in Barcelona, Spain.
Two hundred participants will have overlapping array 
and sequencing characterisation, and will be further anal-
ysed for somatic genetic variance in hereditary cancer 
genes through high read depth targeted-subexome 
sequencing approach.
Active and passive follow-up
Participants will be followed for 20 years after recruit-
ment. At the beginning of 2017, all GCAT participants 
received a newsletter by email acknowledging their partic-
ipation and providing a brief explanation of the study 
status, the goals achieved and the future plans. The first 
active follow-up will start in 2018, and is planned to be 
biannual. Those participants who have been followed 
during at least 2 years received an electronic web-based 
epidemiological questionnaire (only accessible through 
a personalised link) to update or complement baseline 
information. Two reminders are planned to be sent 
in case of non-response (still ongoing). The follow-up 
survey was mainly designed to capture changes in health 
status, lifestyle (ie, smoking, physical activity, alcohol 
intake), dietary habits (validated full-length FFQ), circa-
dian rhythm, shift-work and workplace environment (to 
study occupational diseases), among others.
Deceased participants during follow-up (end point 
ascertainment) will be identified by contrasting the data 
provided by the Spanish National Statistics Institute (www. 
ine. es). The National death statistics data are assembled 
following the WHO criteria, thus, all causes of death are 
classified according to the International Classification of 
Diseases (ICD; http://www. who. int/ classifications/ icd/ 
en/).
The region of Catalonia has an advanced and highly 
developed healthcare system throughout the territory. 
Table 3 Summary of total omic data as of 2017
Study purpose
Number of 
participants Fraction sample Platform Analysed
Metabolomic profile 5000 Plasma NMR MS – 150 metabolites














Subexome 200 Buffy coat Agilent Sureselect/
Illumina paired-end 
SBS
MiSeq (Illumina) Custom multigene 
panel 126 genes 400× 
coverage





analysis at single site and 
regional levels (genes, 
CpG island, promoters, 
enhancers)
EPIC, European Prospective Investigation into Cancer and Nutrition; InDels, insertions-deletions; MS, mass spectrometry; NMR, nuclear 
magnetic resonance; SBS, sequencing by synthesis; SNP, single nucleotide polymorphism.
*Current acquisition.
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The GCAT Study has established a collaboration with the 
Catalan Health Department in order to have access to 
the EHRs of the Catalan Public Healthcare System. This 
registry comprises a huge amount of longitudinal clin-
ical and personal information to promote EHR-driven 
research (ie, disease diagnosis, test reports, billing data, 
treatments, drug dosage/prescription, imaging data, 
biochemical analyses).45 46The EHR access protocol 
guarantees data confidentiality. Therefore, in an anony-
mous manner, the EHR information will be merged with 
the self-reported information that GCAT participants 
contributed at baseline. The EHR access will also allow us 
to follow participants during a long period of time, and to 
obtain a 5-year period retrospective health data.
sample size and statistical power
At the end of 2017, the GCAT Study will have recruited 
20 000 participants, and will be one of the largest prospec-
tive cohort studies in Spain. This will provide a powerful 
approach platform to study a wide range of complex 
diseases and related traits. In the early phases, incident 
cases will be included and analysed as part of a network 
of large cohort consortiums. Prevalent cases identified 
at baseline will provide an opportunity for early results 
based on several pathologies and related traits (table 1).
Statistical power for genetic associations is usually 
expressed by the number of estimated cases of the 
diseases of concern and the assumptions on the expected 
underlying genetic model. Based on the expected 20 000 
participants, considering common conditions with 
2.5%–5% prevalence at baseline, a case size of 500 individ-
uals in a case-control study design (with 1:4 ratio), a power 
of 80%, an alpha level of 0.05, and under an additive 
genetic model (genetic power calculator), the minimum 
detectable statistically significant RR for low frequency 
variants (<5%) in complete linkage disequilibrium will be 
in the range of 1.5–2. Sample size increases by increasing 
the number of tested genetic markers to detect similar RR 
under same assumptions.47 For other approaches, such as 
metabolite analyses, higher RRs are expected, being able 
to detect variation in metabolite concentration from 1% 
(r2 >0.01) for a sample between 1000 and 5000 individ-
uals, with >150 metabolites and 1×106 SNPs.48 The size 
of the GCAT Study was initially settled considering the 
number of new cases expected to occur in the cohort 
along with the magnitude of the effect (RR) to be iden-
tified, as well the exposure prevalence;21 however, this 
is relative and not unarguable when considering such a 
global approach.
data management and analysis plan
Data management
The GCAT Study prospectively assembles data on lifestyle 
and dietary related risk factors. First, all epidemiolog-
ical data collected at baseline will pass through a quality 
control process to ensure validity before examining the 
final data set. All data are collected with Onyx and are 
stored with Opal (the OBiBa’s core database application 
for epidemiological studies),49 and are housed in a secure 
high-performance computing and storage system at 
PMPPC.
Epidemiological and omic data analysis plan
As has been described before, the principal objective 
of GCAT is to prospectively investigate the association 
between epidemiological and genetic risk factors and 
different cancer sites and chronic diseases. Thus, several 
study designs such as cohort studies, nested case-con-
trol studies, cross-sectional studies, retrospective obser-
vational studies and studies based on routine data are 
planned (table 4). As a consequence, different statistical 
approaches will be used.
Molecular profiles will be linked to epidemiological 
data and personal EHRs to evaluate clinical associations 
(ie, cancer, cardiovascular, respiratory and neurological 
diseases, metabolic syndrome, and height). Outcomes of 
interest will evolve throughout the lifetime of the GCAT 
project.
GCAT genomic analysis will be used to characterise 
rare and low frequency variation in the Catalan-Spanish 
population. GCAT genomic profiles will be used to build 
genomic maps including both structural and sequence 
variations, and to create a population-specific sequence-
based reference panel. Family data will be used for haplo-
type inference. A specific GCAT genome browser will 
provide interactive access to the project results.
Genomic quality control on raw genotyping will be 
performed with PLINK V.1.9 software. IMPUTE2 and 
SHAPEIT softwares will be used to impute untyped SNPs 
from sequence-based reference panels. Sequence data 
analyses include comprehensive quality control and the 
alignment reference genome (hg37) with GEM3.50 GATK 
will be used to identify variants, annotate variants to gene 
(Ensembl) and analyse the in silico predicted functional 
impact (PhyloP, PolyPhen2, MutationTaster, CADD and 
GTEx), and population frequency (dbSNP, 1000GP, ExAC 
and Centro Nacional de Análisis Genómico-Centre for 
Genomic Regulation(CNAG-CRG) internal database).
Common and rare and structural genetic variant 
contribution will be analysed for heritable identified 
traits (biological or biomedical) with different predictive 
architectures. Genetic contribution to selected traits will 
be first analysed by GWAS for each variant using a multi-
variate logistic regression analysis. Variant effect size and 
p values will be derived. Whole genomic profile will be 
used for phenotype wide association analysis based on 
comprehensive clinical data from personal EHRs. The 
impact of population admixture will be analysed for clin-
ical relevance based on population history.
Metabolomic and genomic integration will be 
performed to identify underlying genetic variants, as 
well as environmental factors that influence metabolites. 
Plasma metabolite profiles will be analysed for pathway 
analysis and diagnostic biomarker identification, and then 
metabolic quantitative trait analysis will be conducted to 
identify heritable endophenotypes for selected traits.
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FIndIngs to dAte
The GCAT Study is currently finishing the recruitment 
of participants (to be completed by December 2017). 
Among all GCAT participants, 59.2% are women and 
83.3% of the cohort identified themselves as Caucasian/
white. More than half of the participants have higher 
education levels, 72.2% are current workers and 42.1% 
are classified as overweight (BMI ≥25 and <30 kg/m2) 








Baseline assessment Whole cohort Questionnaire, physical measures, 
samples
2014–2017 2018
Repeat of baseline 
assessment
Whole cohort Questionnaire follow-up every 2 years 2018 2019
Genotyping (baseline 
samples)
5459 (GCATcore) Dense genotyping array with 666 695 





5459 (GCATcore) Dense genotyping map with 
15 078 461 variants (see figure 2) by in 
silico imputation (IMPUTE)
2017–2018 2018
Food frequency web 
questionnaire (follow-up)
Whole cohort Participants are invited by email to 
provide additional information about 
diet; estimates of nutrient intake
2017–2018 2018
Biochemical assay (baseline 
samples)





5000 (GCATcore) Biomarkers with known disease 





Whole cohort Participants are invited by email to 
provide additional information (ie, 
sleep behaviour, circadian rhythm, and 
work shift)
2017–2018 2018
Exposome (baseline) Whole cohort Map of environmental exposures 





Whole cohort Participants are invited by email to 
provide additional information via web 
about working places. Information 
will be integrated with exposome 
assessment
2017–2018 2018
Exome 200 (GCATcore) Clinic custom exome of hereditary 
cancer in 126 hereditary cancer genes 
(400×)
2017 2018
Whole-genome sequencing 808 30× whole genome sequencing from 
1000 volunteers, 20% from GCATcore
2017–2018 2018
Epigenome 150 DNA methylation epigenomic profile 




  Primary care Whole cohort ICD/ATC/ OPCS procedures/laboratory 2017–2018 2018
  Death registrations Whole cohort ICD-coded cause specific mortality 2017–2018 2018
  Hospital inpatient Whole cohort ICD/ATC/OPCS procedures/laboratory 2017–2018 2018
  Hospital outpatient Whole cohort ICD (few)/OPCS 2018 2018
  Other Whole cohort National mental healthcare/
national social healthcare
2018 2018
ATC, Anatomical Therapeutic Chemical Classification System; EPIC, European Prospective Investigation into Cancer and Nutrition; 
ICD, International Statistical Classification of Diseases; OPCS, Classification of Interventions and Procedures.
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Table 5 The Genomes for Life (GCAT) Study: summary of 
baseline characteristics
Characteristics Values
Continuous variables Mean (SD)
  Age 51.03 (7.05)
  Heart rate 74.47 (11.12)
  Diastolic blood pressure 78.56 (9.71)
  Systolic blood pressure 123.54 (15.28)
  Age at menarche (among women) 12.38 (1.55)
  Age at menopause (among women) 48.56 (4.74)
  Age at voice change (among men) 14.7 (2.1)
  Age at beard change (among men) 16.0 (2.6)
Categorical variables n (%)
  Gender
   Male 7471 (40.5)
   Female 10 918 (59.2)
   Missing 62 (0.3)
  Marital status
   Married 10 703 (58.0)
   Divorced/separated 2159 (11.7)
   Domestic partner 1142 (6.2)
   Single 1887 (10.2)
   Widow/widower 521 (2.8)
   Missing 2039 (11.1)
  Education level
   Without studies 73 (0.4)
   Elementary education 2104 (11.4)
   Secondary education 4519 (24.5)
   Professional higher education 2037 (11.0)
   Secondary postdegree professional 
programme
2594 (14.1)
   College 6772 (36.7)
   Missing 352 (1.9)
  Ethnicity
   White, Caucasian 15 363 (83.3)
   Hispanic, Latin 2803 (15.2)
   Black 14 (0.1)
   Maghrebin 14 (0.1)
   Gipsy 10 (0.1)
   Asian 1 (0.0)
   Other 18 (0.1)
   Missing 230 (1.2)
  Working status
   Employed 13 327 (72.2)
   Not working/employed 1796 (9.7)
   Retired 1255 (6.8)
   Home maker 1110 (6.0)
Continued
Characteristics Values
   Student 52 (0.3)
   Laboral impairment 376 (2.0)
   Volunteer or unpaid work 126 (0.7)
   Other 206 (1.1)
   Missing 203 (1.1)
  Smoking status
   current, <=15 cig/day 2469 (13.4)
   current, 26+cig/day 148 (0.8)
   current, unknown 318 (1.7)
   current, 16–25 cig/day 752 (4.1)
   former, quit<=10 years 2196 (11.9)
   former, unknown 153 (0.8)
   former, quit 11–20 years 2392 (13.0)
   former, quit 20+ years 1973 (10.7)
   missing 853 (4.6)
   never 7197 (39.0)
  Alcohol consumption
   never or less than once a month 4402 (23.9)
   once per month 1048 (5.7)
   from 2 to 3 times per month 2202 (11.9)
   once per week 3061 (16.6)
   from 2 to 3 times per week 3454 (18.7)
   from 4 to 6 times per week 1059 (5.7)
   once per day 1963 (10.6)
   two or more times per day 1036 (5.6)
   missing 226 (1.2)
  Mediterranean Diet Adherence 
(PrediMed Score)
   Low 2159 (11.7)
   Medium 12 904 (70)
   High 2893 (15.7)
   Missing 495 (2.7)
  Health status
   Very good 3124 (16.9)
   Good 13 080 (70.9)
   Regular 1960 (10.6)
   Bad 126 (0.7)
   Very bad 20 (0.1)
   Missing 141 (0.8)
  Adopted
   Yes 60 (0.3)
   No 18 243 (98.9)
   Missing 148 (0.8)
  Body mass index
   Underweight 47 (0.2)
Table 5 Continued 
Continued
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(table 5). The first active follow-up of the first volunteers 
entering the study will begin in January 2018 and will end 
in March 2018.
Genomic characterisation using array-based technology 
of subcohort (GCATcore data release August 2017), 
(figure 2).
The results of the study will be published in interna-
tional peer-reviewed journals and presented at national 
and international congresses and conferences. Prelimi-
nary data have already been analysed and presented.51 52
dIsCussIon
One of the major strengths of the GCAT Study is its 
prospective design, and that it is one of the largest EHR 
linked-cohort studies in Spain with a deep genome-wide 
characterisation. In addition, blood plasma, blood serum 
and white blood cells were collected and stored at base-
line for each participant. All epidemiological and anthro-
pometric data have been annotated using international 
codification to allow data exchange between national and 
international studies, and to be part of a network of large 
cohort consortiums, as a global strategy on health (ie, 
Genomes of England). Further, detailed information on 
clinical and health status is available for each participant, as 
the GCAT Study has access to EHRs of the Catalan Public 
Healthcare System. The GCAT Study offers a unique oppor-
tunity to integrate epidemiological, environmental, EHR 
and omic factors to investigate the aetiology of chronic 
diseases. Molecular pathological epidemiology is a new 
research area that integrates different fields with the aim 
to study phenotypes of any disease using molecular patho-
logical analyses.53 54 Analyses with germline genomic, epig-
enomic and metabolomic data will provide new results and 
derive new scientific knowledge for public health inter-
ventions (primary and secondary prevention) and towards 
precision medicine for personalised prevention.
Characteristics Values
   Normal weight 6083 (33)
   Overweight 7761 (42.1)
   Obese 4562 (24.7)
   Missing 89 (0.5)
  Women related health
  Oral contraceptive use
   Never 2351 (21.5)
   Ever 8404 (77)
   Missing 163 (1.5)
  Hormone replacement therapy (HRT) 
use
   Never 9280 (85)
   Ever 1317 (12.1)
   Missing 321 (2.9)
  Men related health
  Prostate diseases 660 (8.8)
Two types of variables, continuous (presented in mean (SD)) and 
categorical (which are presented in n(%)) are shown in bold. 
Table 5 Continued 
Figure 2 Number of variants included in the GCATcore by chromosome and type of genomic data (first GCATcore release 
August 2017). The legend shows between parentheses the total number of variants for raw data (genotyping before in silico 
imputation), imputed data, SNPs, Indels and SNPs in coding and non-coding regions. GCAT, Genomes for Life; InDels, 
insertions-deletions; single nucleotide polymorphisms.
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There are a number of challenges that should be acknowl-
edged. The GCAT Study was not designed to achieve a 
representative sample of the Catalan population, since 
non-representativeness does not usually interfere with 
scientific inference.55 56 The GCAT recruitment process 
may have introduced selection bias in our study; however, 
the recruitment was performed through the BST agency to 
enhance participation, and assuring a long-term follow-up 
(20 years). As stated before, our cohort participants are 
mainly health conscious; nevertheless, these participants are 
more likely to participate in intervention studies (which are 
planned at later stages) to evaluate, for instance, behavioural 
and lifestyle habit changes. Further, with a global disease 
approach, the sample size will be a limitation to test for 
genetic associations in any condition even in larger cohorts; 
nonetheless, the deep phenome characterisation of the 
GCAT cohort will allow the implementation of systems 
biology approaches. As the analyses expand (including copy 
number variants, rare alleles and other types of methods) 
more associations will be identified, leading to an increase 
in knowledge of the influence of genomic structure and 
function on health and common diseases.
CollAborAtIon
One of the GCAT characteristics is that it has an open 
protocol that will enable future study designs or procedures 
(ie, family studies, intervention studies). Epidemiolog-
ical data and biological samples are available for external 
researchers. Genotypes (SNPs and InDels) and sequence 
variation data will be sent in a multisample variant call file 
to facilitate further analyses. Qualified researchers who fulfil 
ethical and scientific requirements can submit an applica-
tion form with their personal information, a brief summary 
of the project and specific data/material requested. The 
GCAT scientific committee will evaluate the proposals. 
Before sending biological material and/or data, a data/
material transfer agreement form will be signed among part-
ners to ensure right and duties. All information regarding 
the ethical legal social issues, questionnaire contents and 
available data can be found at www. genomesforlife. com.
ConClusIons
The GCAT Study is a long-term genomic, environmental 
and lifestyle cohort project that aims to evaluate and track 
multiple pathologies as well as biologically related traits. 
Therefore, the GCAT Study offers a unique opportunity to 
integrate diverse data to allow the identification of novel rela-
tions among different biomarkers and conditions. Results 
may lead to the development of new genetic, genomic, 
epigenomic and proteomic diagnoses and screening tests, 
as well as new public health recommendations.
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